What are the precautions for the hot flash drug veozah

Perform baseline blood tests before initiating veozah therapy to evaluate liver function and injury [including serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), and serum bilirubin (total and direct bilirubin)]. Do not initiate veozah therapy if the evaluation laboratory ALT or AST concentration is equal to or exceeds 2 times the ULN, or total bilirubin is elevated (e.g., equal to or exceeds 2 times the ULN).

VEOZAH therapy may be initiated if baseline liver transaminase evaluation is less than 2 times the ULN and total bilirubin is normal. Follow-up evaluations of hepatic transaminase concentrations were performed at 3, 6, and 9 months after initiation of treatment and when symptoms (such as nausea, vomiting, or yellowing of the skin or eyes) suggest liver injury.

There are no data on the use of veozah in pregnant women to evaluate the drug-related risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. The drug is not recommended for pregnant women. Contraceptive measures are required.

There are no data on whether veozah is excreted in human milk, effects on breastfed infants, or effects on lactogenesis. It is not known whether veozah is present in human milk. It is recommended to take medication as directed by your doctor.

Veozah is contraindicated in patients with severe (eGFR 15 to < 30 mL/min/1.73 m 2) renal impairment or end-stage renal disease (eGFR < 15 mL/min/1.73 m 2). Adjustment of veozah is not recommended for patients with mild (eGFR 60 to < 90 mL/min/1.73m 2 ) or moderate (eGFR 30 to < 60 mL/min/1.73m 2 ) renal impairment.

Child-Pugh Class A or B hepatic impairment increases veozah exposure. veozah has not been studied in patients with Child-Pugh Class C hepatic impairment. veozah is contraindicated in patients with cirrhosis.

Inform patients that they must have blood tests to evaluate their liver before starting treatment with veozah and at 3, 6, and 9 months of use, and when clinically indicated for evaluation of signs of abnormal liver symptoms (such as nausea, vomiting, or yellowing of the skin or eyes).

Advise patients to inform their physician of any other prescription or over-the-counter medications or dietary supplements used before use.

Swallow the veozah tablets whole with liquid. Do not cut, crush, or chew tablets. If you miss a dose of veozah, take the missed dose as soon as possible on the same day and at least 12 hours before your next scheduled dose. Return to normal schedule the next day.

A blood test is done to check the patient's liver before they start taking veozah. Blood tests will also be performed at 3, 6 and 9 months after patients start taking veozah.

Veozah is indicated for the treatment of moderate to severe vasomotor symptoms caused by menopause. Its Chinese name is filazonetant. Veozah is stored at 20°C-25°C (68°F-77°F), with an allowed fluctuation range of 15°C-30°C (59°F-86°F). It is recommended that patients take medication under the guidance of a doctor and receive symptomatic treatment.

Recommended related articles: